文献速递流行病学与生物统计临床试验与 GCP医学教育与科研方法

适应性试验的系统调查显示方法学需大幅改进

A systematic survey of adaptive trials shows substantial improvement in methods is needed.
PubMed 文献 · J Clin Epidemiol · 2024-01-11

该研究系统检索了MEDLINE、EMBASE、Cochrane对照试验中心注册库和ClinicalTrials.gov(截至2020年1月),纳入128项自述为适应性试验或应用适应性设计的研究,总结三种常用适应性设计的方法学细节。结果显示中期分析时点与频率报告不足、独立数据监查委员会设立和支撑文件可及性常未说明,作者据此提出14条改进建议。

要点

  • 共纳入128项适应性试验,最常用为成组序贯设计(55.5%)、适应性剂量探索设计(27.3%)和适应性随机化设计(20.3%)。
  • 超过半数适应性随机化试验(57.7%)未报告中期分析时点与频率,三分之二试验(67.2%)未说明设立独立数据监查委员会。
  • 六分之一试验(17.2%)在实施中出现非计划调整,作者据此提出14条改进建议。

核心结论

  • 适应性试验的方法学需大幅改进,尤其是中期分析、独立数据监查委员会设立和非计划调整方面。
  • 作者从通用和具体两方面提出建议,供研究者在设计、实施和分析适应性试验时参考。

研究设计与样本

  • 系统调查:系统检索MEDLINE、EMBASE、Cochrane对照试验中心注册库和ClinicalTrials.gov数据库,截至2020年1月。
  • 纳入自述为适应性试验或应用适应性设计的研究,共128项。
  • 识别三种常用适应性设计并总结其设计、实施和分析的方法学细节,最后提出建议。

主要发现

  • 采用适应性设计的主要动机是加速试验和促进决策(n=29,31.5%)。
  • 最常用的三种方法为成组序贯设计(n=71,55.5%)、适应性剂量探索设计(n=35,27.3%)和适应性随机化设计(n=26,20.3%)。
  • 中期分析时点与频率在四分之三的成组序贯设计试验(n=55,77.5%)和一半的适应性剂量探索设计试验(n=19,54.3%)中有详细说明,但超过半数的适应性随机化设计试验(n=15,57.7%)未提供此信息。
  • 部分试验为中期分析选择了不同于主要结局的指标(成组序贯设计:n=7,12.7%;适应性剂量探索设计:n=8,27.6%;适应性随机化设计:n=7,50.0%),但多数未给出明确理由(成组序贯设计:n=7,100.0%;适应性剂量探索设计:n=7,87.5%;适应性随机化设计:n=5,71.4%)。
  • 超过半数试验(n=76,59.4%)未提及支撑文件的可及性,三分之二(n=86,67.2%)未说明设立独立数据监查委员会,六分之一(n=22,17.2%)在实施中出现非计划调整。

关键数值与推荐

  • 作者基于调查结果提出14条改进适应性试验的建议。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the design, conduct, and analysis of adaptive trials through a systematic survey and provide recommendations for future adaptive trials. STUDY DESIGN AND SETTING: We systematically searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases up to January 2020. We included trials that were self-described as adaptive trials or applied adaptive designs. We identified three frequently used adaptive designs and summarized their methodological details in terms of design, conduct, and analysis. Lastly, we provided recommendations for future adaptive trials. RESULTS: We included a total of 128 trials in this study. The primary motivations for using adaptive design were to speed up the trials and facilitate decision-making (n = 29, 31.5%). The three most frequently used methods were group sequential design (GSD) (n = 71, 55.5%), adaptive dose-finding design (ADFD) (n = 35, 27.3%), and adaptive randomization design (ARD) (n = 26, 20.3%). The timing and frequency of interim analysis were detailed in three-fourths of the GSD trials (n = 55, 77.5%) and in half of the ADFD trials (n = 19, 54.3%); however, more than half of the ARD trials (n = 15, 57.7%) did not provide this information. Some trials selected a different outcome than the primary outcome for interim analysis (GSD: n = 7, 12.7%; ADFD: n = 8, 27.6%; ARD: n = 7, 50.0%), but the majority of these trials did not provide explicit reasons for this choice (GSD: n = 7, 100.0%; ADFD: n = 7, 87.5%; ARD: n = 5, 71.4%). More than half (n = 76, 59.4%) of trials did not mention the accessibility of supporting documents, and two-thirds (n = 86, 67.2%) did not state the establishment of independent data monitoring committees (IDMCs). Moreover, unplanned adjustments were observed during the conduct of one-sixth adaptive trials (n = 22, 17.2%). Based on our findings, we provide 14 recommendations for improving adaptive trials in the future. CONCLUSION: Substantial improvements were needed in methods of adaptive trials, particularly in the areas of interim analysis, the establishment of independent data monitoring committees, and unplanned adjustments. In this study, we offer recommendations from both general and specific aspects for researchers to carefully design, conduct, and analyze adaptive trials.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Yao M, Liu J, et al. A systematic survey of adaptive trials shows substantial improvement in methods is needed. J Clin Epidemiol. 2024. PMID: 38218461. doi:10.1016/j.jclinepi.2024.111257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。